These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 27015118

  • 1. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
    Coppock JD, Vermeer PD, Vermeer DW, Lee KM, Miskimins WK, Spanos WC, Lee JH.
    Oncotarget; 2016 Apr 26; 7(17):24228-41. PubMed ID: 27015118
    [Abstract] [Full Text] [Related]

  • 2. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH.
    Neoplasia; 2013 Jun 26; 15(6):620-30. PubMed ID: 23730210
    [Abstract] [Full Text] [Related]

  • 3. Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis.
    Vermeer DW, Coppock JD, Zeng E, Lee KM, Spanos WC, Onken MD, Uppaluri R, Lee JH, Vermeer PD.
    Oncotarget; 2016 Apr 26; 7(17):24194-207. PubMed ID: 27013584
    [Abstract] [Full Text] [Related]

  • 4. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.
    Molinolo AA, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt S, Patel V, Seiwert TY, Gutkind JS.
    Clin Cancer Res; 2012 May 01; 18(9):2558-68. PubMed ID: 22409888
    [Abstract] [Full Text] [Related]

  • 5. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA, SPECTRUM investigators.
    Lancet Oncol; 2013 Jul 01; 14(8):697-710. PubMed ID: 23746666
    [Abstract] [Full Text] [Related]

  • 6. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ, Guerra-Librero A, Fernandez-Gil BI, Florido J, García-López S, Martinez-Ruiz L, Mendivil-Perez M, Soto-Mercado V, Acuña-Castroviejo D, Ortega-Arellano H, Carriel V, Diaz-Casado ME, Reiter RJ, Rusanova I, Nieto A, López LC, Escames G.
    J Pineal Res; 2018 Apr 01; 64(3):. PubMed ID: 29247557
    [Abstract] [Full Text] [Related]

  • 7. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C, Faber A, Umbreit C, Birk R, Weiss C, Sommer JU, Hörmann K, Schultz JD.
    Anticancer Res; 2015 Apr 01; 35(4):1951-9. PubMed ID: 25862847
    [Abstract] [Full Text] [Related]

  • 8. Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status.
    Du S, Liu K, Gao P, Li Z, Zheng J.
    Life Sci; 2018 Nov 01; 212():182-193. PubMed ID: 30243648
    [Abstract] [Full Text] [Related]

  • 9. Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models.
    Ekshyyan O, Moore-Medlin TN, Raley MC, Sonavane K, Rong X, Brodt MA, Abreo F, Alexander JS, Nathan CA.
    BMC Cancer; 2013 Jul 01; 13():320. PubMed ID: 23815869
    [Abstract] [Full Text] [Related]

  • 10. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.
    Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N.
    Clin Cancer Res; 2017 Dec 01; 23(23):7276-7287. PubMed ID: 28916527
    [Abstract] [Full Text] [Related]

  • 11. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H, Nishiike S, Yamamoto Y, Takenaka Y, Nakahara S, Yasui T, Hanamoto A, Inohara H.
    Auris Nasus Larynx; 2015 Oct 01; 42(5):396-400. PubMed ID: 25721854
    [Abstract] [Full Text] [Related]

  • 12. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Li SH, Lin WC, Huang TL, Chen CH, Chiu TJ, Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, Su YY, Chuang HC, Chien CY.
    Head Neck; 2016 Apr 01; 38 Suppl 1():E844-52. PubMed ID: 25917382
    [Abstract] [Full Text] [Related]

  • 13. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
    Kumar B, Yadav A, Lang JC, Cipolla MJ, Schmitt AC, Arradaza N, Teknos TN, Kumar P.
    Mol Cancer Ther; 2012 Sep 01; 11(9):1988-98. PubMed ID: 22723337
    [Abstract] [Full Text] [Related]

  • 14. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
    Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB.
    Clin Cancer Res; 2012 Oct 01; 18(19):5304-13. PubMed ID: 22859719
    [Abstract] [Full Text] [Related]

  • 15. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
    Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, Glass J, Agarwal A, Caldito G.
    Cancer Res; 2007 Mar 01; 67(5):2160-8. PubMed ID: 17332346
    [Abstract] [Full Text] [Related]

  • 16. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
    Bozec A, Ebran N, Radosevic-Robin N, Sudaka A, Monteverde M, Toussan N, Etienne-Grimaldi MC, Nigro CL, Merlano M, Penault-Llorca F, Milano G.
    Laryngoscope; 2016 Apr 01; 126(4):E156-63. PubMed ID: 26597440
    [Abstract] [Full Text] [Related]

  • 17. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
    Madera D, Vitale-Cross L, Martin D, Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck CM, Walline HM, William WN, Seethala RR, Ferris RL, Gutkind JS.
    Cancer Prev Res (Phila); 2015 Mar 01; 8(3):197-207. PubMed ID: 25681087
    [Abstract] [Full Text] [Related]

  • 18. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN, Osman AA.
    Clin Cancer Res; 2015 Nov 01; 21(21):4831-44. PubMed ID: 26124202
    [Abstract] [Full Text] [Related]

  • 19. Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC.
    Rieke DT, Keilholz U.
    Recent Results Cancer Res; 2017 Nov 01; 206():149-160. PubMed ID: 27699536
    [Abstract] [Full Text] [Related]

  • 20. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
    Lee TK, Poon RT, Wo JY, Ma S, Guan XY, Myers JN, Altevogt P, Yuen AP.
    Cancer Res; 2007 Sep 15; 67(18):8800-9. PubMed ID: 17875721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.